A Phase 4 interventional study of CYP2C19 based dosing Proton Pump Inhibitors and Conventional proton pump inhibitor dose in Gastroesophageal Reflux Disease With Esophagitis, sponsored by University of Florida. Not yet recruiting. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by University of Florida · Phase 4, Interventional, and Treatment
This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.
Exclusion Criteria:
proton pump inhibitor dose based on CYP2C19 phenotypes
Drug: CYP2C19 based dosing Proton Pump Inhibitors
conventional proton pump inhibitor dose of Pantoprazole 40 mg once or twice daily
Drug: Conventional proton pump inhibitor dose
Pantoprazole dosing based on CYP2C19 phenotypes
conventional PPI dose of Pantoprazole 40 mg once or twice daily
Improvement of Los Angeles (LA) classification of Erosive Esphagitis (EE) grade
Assessment of erosive esophagitis grade to determine healing in both arms. Healing would be measured by endoscopic regression of errosive esophagitis (EE) to a lower degree of inflammation. Previously assigned baseline numerical values per the LA classification of EE will be used to calculate the degree of healing in each arm at the 8th week follow up, e.g. LA grade D (initial EGD) to LA grade A (repeat EGD) would yield a score of 3 (LA D \[5\] - LA A \[2\]). A higher score hence indicating superior healing of EE.
Time frame: 8 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Florida